Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Capital Expenditures (2016 - 2021)

Historic Capital Expenditures for Neurocrine Biosciences (NBIX) over the last 12 years, with Q4 2021 value amounting to $8.9 million.

  • Neurocrine Biosciences' Capital Expenditures rose 9777.78% to $8.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $23.4 million, marking a year-over-year increase of 11467.89%. This contributed to the annual value of $38.2 million for FY2024, which is 3498.23% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Capital Expenditures of $8.9 million as of Q4 2021, which was up 9777.78% from $5.7 million recorded in Q3 2021.
  • Neurocrine Biosciences' 5-year Capital Expenditures high stood at $12.4 million for Q3 2018, and its period low was $397000.0 during Q2 2017.
  • In the last 5 years, Neurocrine Biosciences' Capital Expenditures had a median value of $4.1 million in 2019 and averaged $4.0 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Capital Expenditures tumbled by 8857.14% in 2020 and then skyrocketed by 132500.0% in 2021.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' Capital Expenditures stood at $2.4 million in 2017, then skyrocketed by 152.33% to $6.0 million in 2018, then plummeted by 53.32% to $2.8 million in 2019, then soared by 60.71% to $4.5 million in 2020, then surged by 97.78% to $8.9 million in 2021.
  • Its last three reported values are $8.9 million in Q4 2021, $5.7 million for Q3 2021, and $4.3 million during Q2 2021.